Statin use after initiation of androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with a decreased risk of dying from the disease, according to study findings presented at the 34th Annual European Association of Urology Congress in Barcelona, Spain.
In a study that enrolled 8253 men with PCa from the Finnish Randomized Study of Screening for Prostate Cancer, statin use after ADT initiation, compared with nonuse, was associated with a significant 26% decreased risk of death, after adjusting for multiple variables, Antti I. Peltomaa, a doctoral candidate at the University of Tampere in Finland, and colleagues reported. The association was dose dependent, with the middle and highest tertiles of statin use associated with a significant 38% and 48% decreased risk of death, respectively. The lowest tertile was associated with a nonsignificant 12% decreased risk.
Statin use prior to the start of ADT was not associated with PCa death risk or with the risk of starting ADT, according to the investigators.
Of the 8253 men in the study, 4747 used statins and 4428 initiated ADT during follow-up. Among the patients who initiated ADT, the median follow-up time was 6.9 years among statin users and 5.5 years among nonusers.
The investigators defined ADT initiation as the date of surgical orchiectomy or the first prescription of any ADT medication, whichever occurred first.
Peltomaa AI, Murtola TJ, Talala K, et al. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population based cohort study. Presented at the 34th Annual European Association of Urology Congress in Barcelona, Spain, March 15-19. Poster 1040.